经济观察网ST四环(000518)因2024年业绩触及财务类退市指标，已被实施退市风险警示。若2025年经审 计的最终财务数据仍不达标，公司股票可能被终止上市。 近期事件ST四环(股票代码：000518)近期主要热点围绕其退市风险提示。根据公司2026年1月27日发布 的公告，因2024年度净利润为负且营业收入低于3亿元，股票已被实施退市风险警示。若2025年度报告 披露后，经审计的利润指标孰低为负且扣除后营业收入低于3亿元，公司股票可能被终止上市。该风险 提示每十个交易日更新一次，投资者需密切关注后续公告。 以上内容基于公开资料整理，不构成投资建议。 股票近期走势近7天(2026年2月6日至2月12日)，ST四环股价呈现波动下行趋势。区间收盘价从2.61元下 跌至2.55元，累计跌幅约2.3%，振幅达1.57%。2月12日单日跌1.92%，成交额2239万元，换手率 0.85%。技术面显示，股价处于空头行情，20日布林线压力位2.79元，支撑位2.47元，MACD指标偏 弱，反映市场情绪谨慎。 财报分析公司2025年度业绩预告显示，预计净利润亏损3000万元至4000万元，扣非净利润亏损3300万元 至46 ...

Core Viewpoint - Jiangsu Sihuan Biological Co., Ltd. is facing a risk of being delisted due to negative net profit and insufficient revenue as per the Shenzhen Stock Exchange regulations [2][3]. Group 1: Delisting Risk Announcement - The company announced on April 29, 2025, that its stock would be subject to delisting risk warning starting April 30, 2025, due to a negative net profit and revenue below 300 million yuan for the fiscal year 2024 [2][3]. - According to the Shenzhen Stock Exchange's listing rules, if the company continues to meet the criteria for delisting in the following fiscal year, its stock may be terminated from listing [3][11]. Group 2: Financial Performance Indicators - The audited net profit for the fiscal year 2024 was reported as negative, and the operating revenue was below 300 million yuan, triggering the delisting risk warning [3][4]. - The company projected a net profit (excluding non-recurring gains and losses) for 2025 to be between -46 million yuan and -33 million yuan, with expected operating revenue between 330 million yuan and 350 million yuan [11]. Group 3: Compliance and Disclosure Obligations - The company is required to disclose risk warning announcements every ten trading days until the annual report is released, following the initial risk warning announcement [2][11]. - The company will adhere to the information disclosure obligations as stipulated by the Shenzhen Stock Exchange, with designated media for announcements including Securities Times and China Securities Journal [11].

关于公司股票可能被终止上市的第二次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日 披露了《关于公司股票交易被实行退市风险警示暨停牌的公告》（公告编号：临 -2025-24 号），公司股票自 2025 年 4 月 30 日开市起被实施退市风险警示。若 公司出现《深圳证券交易所股票上市规则》（以下简称"《股票上市规则》"） 第 9.3.12 条规定的情形，公司股票存在被终止上市的风险。 股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * ST 四 环 公 告 编 号 ： 临 - 2 0 2 6 - 0 3 号 江苏四环生物股份有限公司 2、根据《股票上市规则》第 9.3.6 条的规定：上市公司因触及本规则第 9.3.1 条第一款第一项至第三项情形，其股票交易被实施退市风险警示后，应当在其股 票交易被实施退市风险警示当年会计年度结束后一个月内，披露股票可能被终止 上市的风险提示公告，在首次风险提示公告披露后至年度报告披露前，每十个交 易日披露 ...

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

Core Viewpoint - The company, Jiangsu Sihuan Bioengineering Co., Ltd., is expected to report a negative net profit for the fiscal year 2025, following a financial warning due to previous losses and low revenue [2][4]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The company anticipates a net profit in the range of -46 million to -33 million yuan, with revenue expected to be between 330 million and 350 million yuan [4][18]. - The forecast data is based on preliminary calculations by the company's finance department and has not been audited by an accounting firm [2][5]. Group 2: Reasons for Performance Changes - The increase in revenue is primarily attributed to significant growth in seedling sales from the wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd. [3]. - The reduction in net losses is due to decreased asset impairment losses and operating expenses, as well as improved cost control by the subsidiary, Beijing Sihuan Biopharmaceutical Co., Ltd. [3]. Group 3: Risk of Delisting - The company's stock will be subject to delisting risk warnings starting April 30, 2025, due to a negative audited net profit and revenue below 300 million yuan for the fiscal year 2024 [4][10]. - If the company fails to meet certain financial criteria in the 2025 annual report, it may face termination of its stock listing [10][17].

Core Viewpoint - *ST SiHuan (000518.SZ) expects a net profit attributable to shareholders of the listed company to be between -40 million to -30 million yuan for the year 2025, with a net profit after deducting non-recurring gains and losses projected to be between -46 million to -33 million yuan [1] Group 1: Financial Performance - The company's revenue growth is primarily attributed to a significant increase in seedling sales from its wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd. [1] - The reduction in net loss year-on-year is mainly due to decreased asset impairment losses and operating expenses, as well as improved cost control measures by its controlling subsidiary, Beijing SiHuan Biological Pharmaceutical Co., Ltd. [1]

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * ST 四 环 公 告 编 号 ： 临 - 2 0 2 6 - 0 2 号 江苏四环生物股份有限公司 关于公司股票可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日 披露了《关于公司股票交易被实行退市风险警示暨停牌的公告》（公告编号：临 -2025-24 号），公司股票自 2025 年 4 月 30 日开市起被实施退市风险警示。若 公司出现《深圳证券交易所股票上市规则》（以下简称"《股票上市规则》"） 第 9.3.12 条规定的情形，公司股票存在被终止上市的风险。 2、根据《股票上市规则》第 9.3.6 条"上市公司因触及本规则第 9.3.1 条 第一款第一项至第三项情形，其股票交易被实施退市风险警示后，应当在其股票 交易被实施退市风险警示当年会计年度结束后一个月内，披露股票可能被终止上 市的风险提示公告，在首次风险提示公告披露后至年度报告披露前，每十个交易 日披露一次风险提 ...

（文章来源：每日经济新闻） 每经AI快讯，1月27日，*ST四环(000518.SZ)公告称，公司2024年度经审计的净利润为负值且营业收入 低于3亿元，股票自2025年4月30日开市起被实施退市风险警示。若公司2025年度报告披露后出现经审计 的利润总额、净利润、扣除非经常性损益后的净利润三者孰低为负值，且扣除后的营业收入低于3亿元 等情形之一的，公司股票将面临被终止上市的风险。公司预计2025年净利润亏损3000万元至4000万元， 预计2025年度扣除非经常性损益后的净利润为-4,600万元至-3,300万元，扣除后营业收入为33,000万元至 35,000万元，该财务数据未经会计师事务所审计，最终财务数据以公司正式披露的经审计后的2025年年 度报告为准。在年度报告披露前，公司将每十个交易日披露一次风险提示公告。 ...

四环生物公告称，2025年营收预计3.4-3.6亿元，上年同期2.04亿元；归属于上市公司股东的净利润预计 亏损4000-3000万元，上年同期亏损1.10亿元，同比增长63.63%-72.73%。营收增长因全资子公司晨薇生 态园苗木销售收入大增；净利润增长因晨薇生态园资产减值损失和营业外支出减少、控股子公司北京四 环生物制药费用控制见效。因2024年净利润为负且营收低于3亿元，公司股票自2025年4月30日起被实施 退市风险警示，若2025年财务指标触及规定情形，股票或终止上市。 ...

四环生物公告称，2025年4月30日起公司股票被实施退市风险警示。依据《股票上市规则》，若2025年 度报告披露后出现规定情形之一，公司股票将面临终止上市风险。公司同日披露业绩预告，预计2025年 度扣非净利润为-4600万元至-3300万元，扣除后营业收入为3.3亿元至3.5亿元，该数据未经审计。在年 报披露前，公司将每十个交易日披露一次风险提示。 ...